Collaboration with Tempus seeks to overcome disparities in structural heart care.
Medtronic has launched the ALERT study, leveraging artificial intelligence (AI) to expand access to transcatheter aortic valve replacement (TAVR) and other heart treatments. Partnering with healthcare AI leader Tempus, the study addresses disparities in care for conditions like severe aortic stenosis (AS) and mitral regurgitation (MR).
Using AI to Bridge the Gap
Tempus’s Tempus Next platform powers the ALERT study by:
- Identifying underserved patients with severe AS or MR.
- Supporting heart teams with efficient patient identification tools.
- Ensuring equitable access to lifesaving treatments.
“AI equips heart teams with a more effective way to identify underserved patients, bringing them closer to the care they need,” said Nina Goodheart, Medtronic’s SVP of Structural Heart & Aortic.
Addressing Urgency in AS Care
Untreated severe AS can be fatal within two years. The ALERT study aims to eliminate barriers and ensure timely interventions, explained Wayne Batchelor, MD, ALERT steering committee chair.
ALERT’s Goals and Implications
Medtronic’s fully funded study will assess Tempus’s AI tools across multiple sites, focusing on:
- Increasing early patient identification.
- Reducing health disparities.
- Shaping future AI-driven cardiology advancements.
By integrating advanced AI tools, Medtronic is paving the way for more equitable and effective cardiovascular care.
Follow MEDWIRE.AI for updates on transformative MedTech innovations.
